Eli Lilly Modifies COVID-19 Purchase Agreement with the US Government
Eli Lilly has modified its purchase agreements with the US government for its emergency use authorized COVID-19 neutralizing antibody therapies, bamlanivimab and etesevimab, to be supplied and used together rather than individually.
Eli Lilly and Company announced on April 12, 2021 that it has modified its purchase agreements with the US government for its emergency use authorized COVID-19 neutralizing antibody therapies, bamlanivimab and etesevimab, to be supplied and used together rather than individually.
Through the modified agreement, the supply of etesevimab will now complement the doses of bamlanivimab that the US government already purchased, concluding the purchase agreement for bamlanivimab alone and cancelling the remaining 350,856 doses that were scheduled to be delivered by the end of March 2021, Eli Lilly said in a company press release.
Currently, bamlanivimab and etesevimab together and bamlanivimab alone have not been approved by FDA, and it is not known if the neutralizing antibody therapies are a safe treatment for COVID-19.
Source: Eli Lilly
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
